What is Rigel Pharmaceuticals Inc's earnings per share (EPS)?

Rigel Pharmaceuticals Inc (RIGL) reported diluted earnings per share of $19.48 for fiscal year 2025. This represents a 1867.7% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Rigel Pharmaceuticals Inc Financials

RIGL

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Rigel Pharmaceuticals Inc (RIGL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 89/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

100

Rigel Pharmaceuticals Inc has an operating margin of 42.6%, meaning the company retains $43 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is up from 13.5% the prior year.

Growth

100

Rigel Pharmaceuticals Inc's revenue surged 64.1% year-over-year to $294.3M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Rigel Pharmaceuticals Inc carries a low D/E ratio of 0.13, meaning only $0.13 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Rigel Pharmaceuticals Inc's current ratio of 2.42 indicates adequate short-term liquidity, earning a score of 45/100. The company can meet its near-term obligations, though with limited headroom.

Returns

100

Rigel Pharmaceuticals Inc earns a strong 93.8% return on equity (ROE), meaning it generates $94 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100. This is down from 531.8% the prior year.

Altman Z-Score Distress

1.42

Rigel Pharmaceuticals Inc scores 1.42, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($508.6M) relative to total liabilities ($122.1M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Piotroski F-Score Neutral

6/9

Rigel Pharmaceuticals Inc passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.21x

For every $1 of reported earnings, Rigel Pharmaceuticals Inc generates $0.21 in operating cash flow ($75.7M OCF vs $367.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage Safe

17.1x

Rigel Pharmaceuticals Inc earns $17.1 in operating income for every $1 of interest expense ($125.5M vs $7.3M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$294.3M

YoY+64.1%

5Y CAGR+22.1%

Rigel Pharmaceuticals Inc generated $294.3M in revenue in fiscal year 2025. This represents an increase of 64.1% from the prior year.

EBITDA

$127.9M

YoY+384.0%

Rigel Pharmaceuticals Inc's EBITDA was $127.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 384.0% from the prior year.

Net Income

$367.0M

YoY+1999.1%

Rigel Pharmaceuticals Inc reported $367.0M in net income in fiscal year 2025. This represents an increase of 1999.1% from the prior year.

EPS (Diluted)

$19.48

YoY+1867.7%

Rigel Pharmaceuticals Inc earned $19.48 per diluted share (EPS) in fiscal year 2025. This represents an increase of 1867.7% from the prior year.

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$40.6M

YoY-28.5%

5Y CAGR+6.0%

10Y CAGR-0.7%

Rigel Pharmaceuticals Inc held $40.6M in cash against $52.5M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

18M

YoY+3.4%

Rigel Pharmaceuticals Inc had 18M shares outstanding in fiscal year 2025. This represents an increase of 3.4% from the prior year.

Margins & Returns

Gross Margin

93.3%

YoY+3.7pp

5Y CAGR-5.8pp

Rigel Pharmaceuticals Inc's gross margin was 93.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.7 percentage points from the prior year.

Operating Margin

42.6%

YoY+29.1pp

5Y CAGR+69.3pp

Rigel Pharmaceuticals Inc's operating margin was 42.6% in fiscal year 2025, reflecting core business profitability. This is up 29.1 percentage points from the prior year.

Net Margin

124.7%

YoY+115.0pp

5Y CAGR+152.1pp

Rigel Pharmaceuticals Inc's net profit margin was 124.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 115.0 percentage points from the prior year.

Return on Equity

93.8%

YoY-438.0pp

5Y CAGR+181.2pp

10Y CAGR+150.1pp

Rigel Pharmaceuticals Inc's ROE was 93.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 438.0 percentage points from the prior year.

Capital Allocation

R&D Spending

$33.3M

YoY+42.4%

5Y CAGR-11.1%

10Y CAGR-6.2%

Rigel Pharmaceuticals Inc invested $33.3M in research and development in fiscal year 2025. This represents an increase of 42.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

N/A

RIGL Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$294.3M+64.1%	$179.3M+53.4%	$116.9M-2.8%	$120.2M-19.4%	$149.2M+37.4%	$108.6M
Cost of Revenue	$19.6M+5.2%	$18.6M+162.3%	$7.1M+306.5%	$1.7M+61.5%	$1.1M+21.0%	$895K
Gross Profit	$274.7M+71.0%	$160.6M+46.3%	$109.8M-7.4%	$118.5M-20.0%	$148.2M+37.5%	$107.7M
R&D Expenses	$33.3M+42.4%	$23.4M-4.7%	$24.5M-59.3%	$60.3M-7.6%	$65.2M+8.5%	$60.1M
SG&A Expenses	$115.9M+2.5%	$113.1M+6.9%	$105.7M-6.0%	$112.5M+22.4%	$91.9M+20.0%	$76.6M
Operating Income	$125.5M+418.6%	$24.2M+218.1%	-$20.5M+63.1%	-$55.5M-344.5%	-$12.5M+56.9%	-$29.0M
Interest Expense	$7.3M-7.6%	$7.9M+15.2%	$6.9M+85.4%	$3.7M-23.7%	$4.9M+259.2%	$1.4M
Income Tax	-$245.2M-27931.7%	$881K	$0	N/A	$605K	N/A
Net Income	$367.0M+1999.1%	$17.5M+169.7%	-$25.1M+57.2%	-$58.6M-227.0%	-$17.9M+39.8%	-$29.7M
EPS (Diluted)	$19.48+1867.7%	$0.99+168.7%	$-1.44	$-3.44-3027.3%	$-0.11+38.9%	$-0.18

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$69.8M+0.5%	$69.5M-31.7%	$101.7M+90.7%	$53.3M-7.4%	$57.6M+4.1%	$55.3M+50.1%	$36.8M+24.7%	$29.5M
Cost of Revenue	$6.0M+25.3%	$4.8M+5.5%	$4.5M+2.2%	$4.4M-23.8%	$5.8M-27.9%	$8.0M+185.9%	$2.8M+38.6%	$2.0M
Gross Profit	$63.8M-1.3%	$64.7M-33.4%	$97.2M+98.6%	$48.9M-5.6%	$51.8M+9.6%	$47.3M+38.9%	$34.0M+23.7%	$27.5M
R&D Expenses	$10.7M+45.3%	$7.4M+7.8%	$6.8M-19.1%	$8.4M+49.8%	$5.6M-8.9%	$6.2M+11.6%	$5.5M-8.1%	$6.0M
SG&A Expenses	$30.0M+3.6%	$28.9M-1.1%	$29.3M+5.6%	$27.7M-6.1%	$29.5M+9.2%	$27.0M-3.6%	$28.0M-1.4%	$28.4M
Operating Income	$23.2M-18.5%	$28.4M-53.5%	$61.1M+378.4%	$12.8M-23.3%	$16.7M+18.5%	$14.1M+3044.5%	$447K+106.4%	-$7.0M
Interest Expense	$1.7M-10.3%	$1.9M+1.1%	$1.9M+1.1%	$1.9M-5.2%	$2.0M-5.1%	$2.1M+1.5%	$2.0M+8.3%	$1.9M
Income Tax	-$245.4M-87525.4%	-$280K-175.9%	$369K+467.7%	$65K-92.6%	$881K	$0	$0	$0
Net Income	$268.1M+860.8%	$27.9M-53.2%	$59.6M+420.8%	$11.4M-20.2%	$14.3M+15.5%	$12.4M+1305.9%	-$1.0M+87.5%	-$8.2M
EPS (Diluted)	N/A	$1.46-55.5%	$3.28+420.6%	$0.63	N/A	$0.70+1266.7%	$-0.06	$-0.47

RIGL Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$513.6M+213.2%	$164.0M+39.9%	$117.2M-12.7%	$134.3M-19.8%	$167.3M+51.6%	$110.4M
Current Assets	$240.2M+77.8%	$135.1M+36.1%	$99.3M-14.4%	$115.9M-25.0%	$154.5M+73.6%	$89.0M
Cash & Equivalents	$40.6M-28.5%	$56.7M+73.1%	$32.8M+34.0%	$24.5M+29.5%	$18.9M-37.8%	$30.4M
Inventory	$11.5M+91.7%	$6.0M+8.7%	$5.5M-39.4%	$9.1M+37.8%	$6.6M+303.9%	$1.6M
Accounts Receivable	$51.8M+24.4%	$41.6M+36.2%	$30.6M-24.2%	$40.3M+160.6%	$15.5M-3.1%	$16.0M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$122.1M-24.0%	$160.7M+10.2%	$145.9M-1.4%	$147.9M+8.0%	$137.0M+79.4%	$76.4M
Current Liabilities	$99.2M+56.8%	$63.3M+18.8%	$53.3M-18.3%	$65.2M+2.6%	$63.6M+55.6%	$40.8M
Long-Term Debt	$52.5M-12.5%	$60.0M0.0%	$60.0M+50.0%	$40.0M+100.0%	$20.0M0.0%	$20.0M
Total Equity	$391.5M+11806.3%	$3.3M+111.5%	-$28.6M-110.4%	-$13.6M-144.8%	$30.4M-10.7%	$34.0M
Retained Earnings	-$1.0B+26.4%	-$1.4B+1.2%	-$1.4B-1.8%	-$1.4B-4.4%	-$1.3B-1.4%	-$1.3B

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$513.6M+111.8%	$242.5M+17.3%	$206.7M+17.5%	$176.0M+7.3%	$164.0M+17.6%	$139.4M+8.6%	$128.4M+1.5%	$126.5M
Current Assets	$240.2M+11.7%	$214.9M+22.5%	$175.4M+19.7%	$146.6M+8.5%	$135.1M+26.9%	$106.5M+12.4%	$94.7M+2.4%	$92.5M
Cash & Equivalents	$40.6M-16.4%	$48.5M-9.1%	$53.4M+16.8%	$45.7M-19.4%	$56.7M+9.8%	$51.7M+43.4%	$36.1M+41.0%	$25.6M
Inventory	$11.5M-13.5%	$13.3M+27.6%	$10.4M+123.7%	$4.7M-22.4%	$6.0M+25.5%	$4.8M-40.6%	$8.1M+22.5%	$6.6M
Accounts Receivable	$51.8M+12.7%	$45.9M+15.1%	$39.9M-3.9%	$41.5M-0.2%	$41.6M+36.1%	$30.6M+5.8%	$28.9M+5.1%	$27.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$122.1M-2.3%	$124.9M+0.1%	$124.8M-20.7%	$157.4M-2.0%	$160.7M+4.3%	$154.1M-2.7%	$158.3M+0.1%	$158.2M
Current Liabilities	$99.2M+5.1%	$94.4M+9.0%	$86.6M+30.0%	$66.6M+5.3%	$63.3M+16.5%	$54.3M-7.4%	$58.6M-19.9%	$73.2M
Long-Term Debt	$52.5M-12.5%	$60.0M0.0%	$60.0M0.0%	$60.0M0.0%	$60.0M0.0%	$60.0M0.0%	$60.0M0.0%	$60.0M
Total Equity	$391.5M+232.9%	$117.6M+43.5%	$81.9M+341.3%	$18.6M+464.7%	$3.3M+122.5%	-$14.6M+51.1%	-$29.9M+5.5%	-$31.7M
Retained Earnings	-$1.0B+20.8%	-$1.3B+2.1%	-$1.3B+4.3%	-$1.4B+0.8%	-$1.4B+1.0%	-$1.4B+0.9%	-$1.4B-0.1%	-$1.4B

RIGL Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$75.7M+140.4%	$31.5M+648.0%	-$5.7M+92.2%	-$73.8M-1354.8%	$5.9M+111.3%	-$52.2M
Capital Expenditures	N/A	N/A	N/A	$450K-28.2%	$627K-50.3%	$1.3M
Free Cash Flow	N/A	N/A	N/A	-$74.2M-1513.2%	$5.3M+109.8%	-$53.4M
Investing Cash Flow	-$92.4M-2336.4%	$4.1M+196.1%	-$4.3M-105.9%	$72.8M+190.9%	-$80.0M-268.6%	$47.5M
Financing Cash Flow	$601K+105.2%	-$11.6M-163.4%	$18.4M+180.4%	$6.5M-89.5%	$62.7M+398.6%	$12.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$22.0M-8.5%	$24.0M-21.3%	$30.5M+3519.6%	-$893K-106.2%	$14.5M-33.1%	$21.7M+7078.5%	$302K+106.0%	-$5.0M
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	-$25.4M+23.6%	-$33.2M-42.5%	-$23.3M-120.6%	-$10.6M+3.3%	-$10.9M-387.1%	$3.8M-65.2%	$10.9M+3391.7%	$313K
Financing Cash Flow	-$4.6M-207.0%	$4.3M+921.8%	$418K-13.6%	$484K-67.0%	$1.5M+114.9%	-$9.8M-1208.8%	-$752K+70.1%	-$2.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RIGL Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	93.3%+3.7pp	89.6%-4.3pp	93.9%-4.6pp	98.6%-0.7pp	99.3%+0.1pp	99.2%
Operating Margin	42.6%+29.1pp	13.5%+31.0pp	-17.5%+28.7pp	-46.2%-37.8pp	-8.4%+18.3pp	-26.7%
Net Margin	124.7%+115.0pp	9.8%+31.2pp	-21.5%+27.2pp	-48.7%-36.7pp	-12.0%+15.4pp	-27.4%
Return on Equity	93.8%-438.0pp	531.8%	N/A	N/A	-59.0%+28.4pp	-87.4%
Return on Assets	71.5%+60.8pp	10.7%+32.1pp	-21.4%+22.2pp	-43.6%-32.9pp	-10.7%+16.2pp	-27.0%
Current Ratio	2.42+0.3	2.13+0.3	1.86+0.1	1.78-0.7	2.43+0.3	2.18
Debt-to-Equity	0.13-18.1	18.25+20.3	-2.09+0.8	-2.94-3.6	0.66+0.1	0.59
FCF Margin	N/A	N/A	N/A	-61.7%-65.2pp	3.5%+52.7pp	-49.2%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	91.5%-1.7pp	93.2%-2.4pp	95.6%+3.8pp	91.7%+1.8pp	90.0%+4.5pp	85.5%-6.9pp	92.4%-0.8pp	93.1%
Operating Margin	33.2%-7.7pp	40.9%-19.2pp	60.1%+36.1pp	23.9%-5.0pp	28.9%+3.5pp	25.4%+24.2pp	1.2%+24.8pp	-23.6%
Net Margin	384.0%+343.9pp	40.2%-18.5pp	58.6%+37.2pp	21.5%-3.4pp	24.9%+2.4pp	22.5%+25.3pp	-2.8%+25.1pp	-27.9%
Return on Equity	68.5%+44.8pp	23.7%-49.0pp	72.8%+11.1pp	61.7%-374.5pp	436.2%	N/A	N/A	N/A
Return on Assets	52.2%+40.7pp	11.5%-17.3pp	28.8%+22.3pp	6.5%-2.2pp	8.8%-0.2pp	8.9%+9.7pp	-0.8%+5.7pp	-6.5%
Current Ratio	2.42+0.1	2.28+0.3	2.02-0.2	2.20+0.1	2.13+0.2	1.96+0.3	1.62+0.4	1.26
Debt-to-Equity	0.13-0.4	0.51-0.2	0.73-2.5	3.23-15.0	18.25+22.3	-4.10-2.1	-2.01-0.1	-1.89
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Palvella Therapeutics Inc PVLA

$1.8B

Nurix Therapeutics, Inc. NRIX

$1.6B

Rezolute Inc RZLT

$298.6M

Terns Pharmaceuticals, Inc. TERN

$6.1B

Anaptysbio Inc ANAB

$1.7B

Frequently Asked Questions

What is Rigel Pharmaceuticals Inc's annual revenue?

Rigel Pharmaceuticals Inc (RIGL) reported $294.3M in total revenue for fiscal year 2025. This represents a 64.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Rigel Pharmaceuticals Inc's revenue growing?

Rigel Pharmaceuticals Inc (RIGL) revenue grew by 64.1% year-over-year, from $179.3M to $294.3M in fiscal year 2025.

Is Rigel Pharmaceuticals Inc profitable?

Yes, Rigel Pharmaceuticals Inc (RIGL) reported a net income of $367.0M in fiscal year 2025, with a net profit margin of 124.7%.

What is Rigel Pharmaceuticals Inc's EBITDA?

Rigel Pharmaceuticals Inc (RIGL) had EBITDA of $127.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Rigel Pharmaceuticals Inc have?

As of fiscal year 2025, Rigel Pharmaceuticals Inc (RIGL) had $40.6M in cash and equivalents against $52.5M in long-term debt.

What is Rigel Pharmaceuticals Inc's gross margin?

Rigel Pharmaceuticals Inc (RIGL) had a gross margin of 93.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Rigel Pharmaceuticals Inc's operating margin?

Rigel Pharmaceuticals Inc (RIGL) had an operating margin of 42.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Rigel Pharmaceuticals Inc's net profit margin?

Rigel Pharmaceuticals Inc (RIGL) had a net profit margin of 124.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Rigel Pharmaceuticals Inc's return on equity (ROE)?

Rigel Pharmaceuticals Inc (RIGL) has a return on equity of 93.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Rigel Pharmaceuticals Inc's operating cash flow?

Rigel Pharmaceuticals Inc (RIGL) generated $75.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Rigel Pharmaceuticals Inc's total assets?

Rigel Pharmaceuticals Inc (RIGL) had $513.6M in total assets as of fiscal year 2025, including both current and long-term assets.

How much does Rigel Pharmaceuticals Inc spend on research and development?

Rigel Pharmaceuticals Inc (RIGL) invested $33.3M in research and development during fiscal year 2025.

How many shares does Rigel Pharmaceuticals Inc have outstanding?

Rigel Pharmaceuticals Inc (RIGL) had 18M shares outstanding as of fiscal year 2025.

What is Rigel Pharmaceuticals Inc's current ratio?

Rigel Pharmaceuticals Inc (RIGL) had a current ratio of 2.42 as of fiscal year 2025, which is generally considered healthy.

What is Rigel Pharmaceuticals Inc's debt-to-equity ratio?

Rigel Pharmaceuticals Inc (RIGL) had a debt-to-equity ratio of 0.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Rigel Pharmaceuticals Inc's return on assets (ROA)?

Rigel Pharmaceuticals Inc (RIGL) had a return on assets of 71.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Rigel Pharmaceuticals Inc's Altman Z-Score?

Rigel Pharmaceuticals Inc (RIGL) has an Altman Z-Score of 1.42, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Rigel Pharmaceuticals Inc's Piotroski F-Score?

Rigel Pharmaceuticals Inc (RIGL) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Rigel Pharmaceuticals Inc's earnings high quality?

Rigel Pharmaceuticals Inc (RIGL) has an earnings quality ratio of 0.21x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Rigel Pharmaceuticals Inc cover its interest payments?

Rigel Pharmaceuticals Inc (RIGL) has an interest coverage ratio of 17.1x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Rigel Pharmaceuticals Inc?

Rigel Pharmaceuticals Inc (RIGL) scores 89 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.